AEye, Inc. Enters ATM Sales Agreement to Raise Up to $50M

What Happened
AEye, Inc. announced on September 15, 2026 that it entered into an At‑Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to offer and sell up to $50,000,000 of its common stock from time to time. The Placement Shares will be sold pursuant to AEye’s Form S‑3 shelf (Reg. No. 333‑296038); a prospectus supplement dated September 15, 2026 was filed in connection with the offering. The company said proceeds will be used for working capital and general corporate purposes, including R&D, commercial expansion (including aerospace & defense and infrastructure markets), capital expenditures, and G&A.

Key Details

• Agreement date: September 15, 2026.
• Maximum offering size: Up to $50,000,000 of common stock, sold “at‑the‑market” (including on Nasdaq).
• Placement agent & fees: A.G.P. acting as sales agent; cash commission up to 3.0% of gross proceeds.
• Advisor fees & expenses: Craig‑Hallum Capital Group LLC to receive advisory fees up to 1.0% of gross proceeds; A.G.P. reimbursed for certain out‑of‑pocket costs (up to $50,000 for agreement execution and up to $5,000 per due‑diligence update, capped at $15,000 per fiscal year).
• Duration/termination: Offering ends on the earliest of (i) 36 months after the prospectus supplement, (ii) sale of all Placement Shares, or (iii) agreement termination; either party may terminate on 30 days’ notice. The company is not obligated to sell any shares and may suspend sales at any time.
• Other filings: Legal opinion from Allen & Overy Shearman Sterling US LLP filed as Exhibit 5.1.

Note: Item 1.02 of the filing references termination of a material definitive agreement in connection with this new Sales Agreement; the excerpt provided does not include further details.

Why It Matters
This gives AEye a flexible, on‑demand way to raise up to $50M of capital without a single large transaction — useful for funding growth initiatives while timing sales to market conditions. Any shares sold will dilute existing shareholders, and underwriting/ advisory fees (up to 3% + up to 1%) and expense reimbursements will reduce net proceeds. Investors should watch for future 8‑K or 10‑Q updates that disclose actual share sales, dilution impacts, and how the company uses the proceeds.